US Stock Market News | Novavax Pharmaceuticals plunges over 19% as FDA halts its flu vaccine clinical trial
On Wednesday, Novavax's stock price fell sharply, with the stock dropping over 19% to $10.16 as of the time of publication. On the news front, the U.S. Food and Drug Administration (FDA) has paused the company's planned clinical trial of a flu vaccine. The clinical hold was due to a spontaneously reported severe adverse event of motor neuron disease in a single participant in the Phase 2 trial
According to Zhitong Finance APP, on Wednesday, Novavax (NVAX.US) saw a significant drop in stock price, with the stock falling over 19% to $10.16 at the time of publication. On the news front, the U.S. Food and Drug Administration (FDA) has paused the company's planned clinical trial of a flu vaccine. The clinical hold was initiated due to a spontaneously reported severe adverse event of transverse myelitis in a single participant in the Phase 2 trial